What is GHK-Cu? What it does, benefits and what the evidence shows

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to a copper ion) first identified in human plasma in 1973. As a topical skincare ingredient, it has decades of use and a set of small, mostly older human studies behind it. As an injectable, which is a newer trend, it has essentially none — and that's the split that matters most when you're trying to figure out what's actually been shown.

What GHK-Cu is and how it works

GHK-Cu occurs naturally in the body and can also be released from tissue after injury, which is part of why researchers got interested in it as a wound-healing signal in the first place (PMC review, "Regenerative and Protective Actions of the GHK-Cu Peptide"). For decades, its effects were attributed mainly to copper delivery — the peptide binds a copper ion and helps shuttle it into cells, where copper acts as a cofactor for several healing-related enzymes. More recent work using large public gene-expression datasets (the Broad Institute's Connectivity Map) found that GHK-Cu changes expression of a large number of human genes — roughly a third of tested genes shifted by 50% or more in cell-based assays, some up and some down — which the review's authors, including the peptide's discoverer, describe as an important additional mechanism alongside copper delivery (PMC review).

In skin specifically, that translates into stimulating fibroblasts to produce more collagen and elastin, along with anti-inflammatory and antioxidant effects and support for new blood vessel formation, according to both cell studies and topical human trials (PMC review).

What people use it for

What the research actually shows

Topical use: the part with some human data

This is where GHK-Cu has human data, but it's thinner than the numbers below suggest. The review those numbers come from was written by the peptide's discoverer, Loren Pickart, and it traces the facial-cream and eye-cream studies to 2002 conference proceedings and the collagen comparison to a 1998 pilot study (Pickart and Margolina, Int J Mol Sci, 2018). NPR describes the controlled human studies as "generally small trials funded by the cosmetic industry" (NPR), and independent reviews are cautious: a 2025 review found "a surprising absence of clinical studies" on GHK-Cu as an anti-wrinkle ingredient (Mortazavi et al., BioImpacts, 2025), and 2026 reviews call the clinical literature thin and sparse (Najafi et al., 2026; Mateescu et al., Pharmaceutics, 2026), one noting a 13-participant post-laser study that was negative on objective endpoints. Here is what the earlier studies reported. A 12-week facial cream study in 71 women with photoaging, presented at a 2002 dermatology meeting, reported increased skin density, reduced laxity and improved clarity. A separate 12-week eye-cream study in 41 women, presented at the same meeting, reported better results than placebo and a vitamin K cream. In a 1998 pilot study, GHK-Cu applied to thigh skin for 12 weeks improved collagen production in 70% of the women treated, versus 50% with a vitamin C cream and 40% with a retinoic acid cream (PMC review, summarizing multiple trials). Reporting on this same body of evidence, NPR notes that "topical copper peptide serums and creams have been on the market for decades and studied in human trials," and that studies have found GHK-Cu stimulates collagen production, triggers new blood vessel growth in skin, and has anti-inflammatory effects (NPR, September 7, 2026).

This is also the use case where GHK-Cu is regulated as a cosmetic ingredient rather than as a drug, and it's why it shows up on ingredient labels (commonly listed as a copper tripeptide) in ordinary skincare products without needing FDA drug approval — cosmetics don't require that kind of approval as long as the marketing doesn't make disease-treatment claims.

Hair growth is a thinner story than skin. NPR says controlled human studies have covered hair growth only to a lesser extent than skin, and a 2026 review describes a small 18-participant split-face eyebrow study that reported positive cosmetic hair outcomes but did not define the GHK-Cu form or local exposure (Mateescu et al., Pharmaceutics, 2026). We treat hair growth as limited evidence rather than folding it into the stronger skin data above (NPR).

Injectable/systemic use: animal data only, and NPR reports no published human data

The animal literature on injected or systemic GHK-Cu is real: the Pickart and Margolina review reports that GHK-Cu given systemically to mice, rats and pigs protected against the impaired wound healing caused by cortisone, and a mouse study found that GHK-Cu injected intraperitoneally before an inflammatory challenge reduced inflammatory markers and lung tissue damage in a model of acute lung injury (PMC review; PMC, acute lung injury in mice).

What doesn't exist, as of a September 2026 NPR report on the injecting trend, is human data: "there is no data from published human studies to show this practice is safe and effective." Dermatologist David Goldberg told NPR, "I'm not going to sleep well at night, until the human studies are actually done." Erik Marks, a doctor of nursing practice who runs a wellness clinic and sees patients who injected it on their own, told NPR the problems he sees range from "injection site irritation and infections to more serious problems affecting the liver" ("their liver enzymes are elevated, copper is elevated – they've been injecting way too much"), and NPR adds that it's unclear whether the copper peptide or some other undisclosed substance or impurity was responsible. NPR also reports that in his clinical experience "the topicals work much better for skin and hair growth" than injecting does (NPR, September 7, 2026). That's one clinician's on-the-record experience, not a trial, but it points the same way: the newer, riskier route doesn't obviously outperform the older, better-studied one.

Side effects and risks

Topically, GHK-Cu's safety record is genuinely long: its discoverer's own review says it "has been widely used in anti-aging and cosmetic products in humans for decades without any adverse effects," which is an author's summary rather than a systematic safety analysis (PMC review). That record does not transfer to injecting it, which delivers the peptide systemically rather than to the skin's surface and bypasses the controls that come with a regulated cosmetic product. FDA's page on compounding bulk substances lists injectable GHK-Cu among the substances "nominated but withdrawn" (previously in its safety-risk category 2 until the nominators withdrew them, which is not an approval), noting a possible immunogenicity risk and limited human data on safety (FDA, content current as of 04/22/2026).

NPR's reporting lists the specific risks of injection: overloading the body with too much copper, and triggering a dangerous immune reaction (NPR attributes these to Warren Ladiges, a University of Washington School of Medicine professor who has studied the peptide and considers it generally safe based on animal studies) — both mechanistically plausible given that copper is a metal the body tightly regulates, not something to introduce in unmeasured amounts. Beyond the biology, there's a sourcing problem: dermatologist Marisa Garshick told NPR that "whether or not it's even a copper peptide is always a concern," and that "the stakes are much higher when you're injecting something" versus applying it to skin, where a contaminated or mislabeled product is far less consequential (NPR).

Grey-market GHK-Cu vials show a specific, measurable version of that sourcing problem: purity is excellent, but fill amount is not. In our data as of September 29, 2026, 25 of 26 GHK-Cu vials with a purity result came in at 99% or higher, with a median purity of 99.90% — as clean as anything in our database. Fill amount is a different story: of 28 vials with a measured amount, the median ran 15.2% over label, only 5 landed within ±5%, and 14 measured more than 20% over label — with 10 of those measuring more than 50% over. All 10 of GHK-Cu's failed vials in our data failed specifically because of that overfill, not because of purity. Nothing in our data speaks to whether an injected vial is the copper peptide it claims to be at the molecular level versus something else entirely — that's outside what a standard purity/dose lab report checks, and it's exactly the concern Garshick raised about sourcing above.

It's worth sitting with why overfill would be the dominant failure mode for this specific compound rather than, say, underfill or contamination. We don't have a verified explanation in our data — we can only report the pattern, not the cause — but it's a useful reminder that "high purity" and "correct amount" are two separate checks that can move in opposite directions on the same vial, which is exactly why a lab report needs to state both rather than either alone.

What the lab tests show

Today, our database includes 29 GHK-Cu vials from 9 vendors, drawn from 16 lab reports dated February 2025 through August 2026. As noted above, as of September 29, 2026, purity is the strongest part of this compound's record (median 99.90%, none under 95%) while fill amount is the weak point: median +15.2% over label, with 10 of 29 vials (about a third) measuring more than 50% over — and all 10 of GHK-Cu's failures in our data trace back to that overfill pattern rather than to contamination or underfill. That's an unusual profile compared with most compounds we track: excellent purity paired with a genuinely unreliable fill amount.

That's a small sample — 9 vendors and about 16 reports as of September 29, 2026 — so a single vendor's results can shift these numbers meaningfully; treat this as a snapshot rather than a settled picture. Here's how the ranked vendors for GHK-Cu look right now; the table shows current verdicts and flags any vendor whose failed-vial rate runs above 5%, which given the overfill pattern above may include more vendors than for a typical compound:

Buying smarter

If you're specifically interested in injectable use, weigh the fact that NPR reports no published human safety or efficacy data for that route, regardless of how well-studied the topical form is — those are two different products in the eyes of the evidence, not one product used two ways. Check a specific vendor's record on the GHK-Cu results page before trusting any single report, keeping in mind a vendor needs at least five lab reports before we rank them.

Given how sharply this compound's fill amount can run over label, a quantity test is the single most useful check you can order on a vial you already have — purity has rarely been the problem here. How to get a peptide tested covers ordering independent identity, purity and quantity testing; how to read a peptide COA and fake peptide COAs cover what to check on any report a vendor hands you before you trust it. If your own vial fails, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify.

Worth being explicit about what a standard lab report does and doesn't settle for this compound specifically. A purity and quantity test tells you how much of the labeled peptide is actually in the vial and how clean it is — genuinely useful information given how far fill amounts have run from label in our data. It does not tell you whether injecting the contents is a good idea, and it doesn't test for the copper-overload or immune-reaction risks the dermatologists above raised, which are about the injection route itself rather than about what's dissolved in the vial. If your interest in GHK-Cu is the topical, cosmetic evidence described earlier in this article, that evidence has nothing to do with injecting it — it's a different route of administration with its own, currently unanswered, safety questions.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice. GHK-Cu is widely used as a cosmetic ingredient in topical skincare, but injectable use is untested in published human studies and is sold, where available, for research use only.